Obesity

U.S. FDA approves ANDA for generic drug for short-term management of obesity

Published in Obesity and Diabetes Week, May 16th, 2005

Lannett Company, Inc. (LCI) announced it has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of phentermine hydrochloride tablets 37.5 mg. The company expects to commence marketing this product in June, 2005.

Phentermine hydrochloride is indicated for the short-term management of obesity and is the generic equivalent of Adipex-P, marketed by Gate Pharmaceuticals, a division of Teva Pharmaceutical Industries.

According to NDC Health (originally National Data Corporation), the total U.S. market for Phentermine Hydrochloride 37.5 mg tablets is approximately $84 million. Currently, there...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-05-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry